Back to company

Novo Nordisk Invest 4 A/S: Financial statements 2018

CVR: 31853923

Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2018. In 2018, the company reported a net result of DKK 189,000 compared with DKK -775,000 the year before. Equity amounted to DKK 9,315,000. The solvency ratio was 91.4%.

Profit/Loss
189,000 kr.
Equity
9,315,000 kr.
Total Assets
10,188,000 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018--189 t.9.3 mio.-
2017---775 t.9.1 mio.-
2016---407 t.9.9 mio.-
2015219.3 mio.-803 t.10.3 mio.-
2013181.8 mio.--214 t.5.7 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Novo Nordisk Invest 4 A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2018

Tomas Haagen joins the board of Novo Nordisk Invest 4 A/SOct 1, 2018

As of October 1, 2018, Tomas Haagen has joined the board of directors of Novo Nordisk Invest 4 A/S.

Ole Falvig Ramsby leaves the board of Novo Nordisk Invest 4 A/SOct 1, 2018

As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Invest 4 A/S.

Novo Nordisk Invest 4 A/S: The 2017 annual report is outMay 16, 2018

Novo Nordisk Invest 4 A/S has published its annual report for 2017. The net result was DKK -775,000.

Karsten Munk Knudsen joins the board of Novo Nordisk Invest 4 A/SApr 25, 2018

As of April 25, 2018, Karsten Munk Knudsen has joined the board of directors of Novo Nordisk Invest 4 A/S.

Jesper Brandgaard leaves the board of Novo Nordisk Invest 4 A/SApr 25, 2018

As of April 25, 2018, Jesper Brandgaard has left the board of directors of Novo Nordisk Invest 4 A/S.

Peter Bøggild joins Novo Nordisk Invest 4 A/S as directorApr 25, 2018

As of April 25, 2018, Peter Bøggild is registered as director of Novo Nordisk Invest 4 A/S.

Karsten Munk Knudsen steps down as director of Novo Nordisk Invest 4 A/SApr 25, 2018

As of April 25, 2018, Karsten Munk Knudsen has stepped down as director of Novo Nordisk Invest 4 A/S.

About Novo Nordisk Invest 4 A/S

Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.